Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 739

1.

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone.

Melamed-Gal S, Loupe P, Timan B, Weinstein V, Kolitz S, Zhang J, Funt J, Komlosh A, Ashkenazi N, Bar-Ilan O, Konya A, Beriozkin O, Laifenfeld D, Hasson T, Krispin R, Molotsky T, Papir G, Sulimani L, Zeskind B, Liu P, Nock S, Hayden MR, Gilbert A, Grossman I.

eNeurologicalSci. 2018 May 30;12:19-30. doi: 10.1016/j.ensci.2018.05.006. eCollection 2018 Sep.

2.

Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.

Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Clin Pharmacol Ther. 2018 Jul 12. doi: 10.1002/cpt.1179. [Epub ahead of print]

PMID:
29999516
3.

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.

Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR.

BMC Biol. 2018 Jun 27;16(1):58. doi: 10.1186/s12915-018-0526-3.

4.

A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease.

Martin DDO, Kay C, Collins JA, Nguyen YT, Slama RA, Hayden MR.

Sci Rep. 2018 May 25;8(1):8096. doi: 10.1038/s41598-018-25903-w.

5.

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.

Mol Neurodegener. 2018 May 21;13(1):25. doi: 10.1186/s13024-018-0259-3.

6.

A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.

Petrella LI, Castelhano JM, Ribeiro M, Sereno JV, Gonçalves SI, Laço MN, Hayden MR, Rego AC, Castelo-Branco M.

Hum Mol Genet. 2018 Jun 15;27(12):2125-2137. doi: 10.1093/hmg/ddy119.

PMID:
29668904
7.

Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli.

Ladha S, Qiu X, Casal L, Caron NS, Ehrnhoefer DE, Hayden MR.

Cell Death Discov. 2018 Mar 12;4:40. doi: 10.1038/s41420-018-0043-8. eCollection 2018.

8.

Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.

Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR.

Acta Neuropathol Commun. 2018 Mar 6;6(1):16. doi: 10.1186/s40478-018-0518-0.

9.

Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice.

Chevre R, Trigueros-Motos L, Castaño D, Chua T, Corlianò M, Patankar JV, Sng L, Sim L, Juin TL, Carissimo G, Ng LFP, Yi CNJ, Eliathamby CC, Groen AK, Hayden MR, Singaraja RR.

FASEB J. 2018 Jul;32(7):3792-3802. doi: 10.1096/fj.201701084RR. Epub 2018 Feb 26.

PMID:
29481310
10.

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population.

Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):346-357. doi: 10.1002/ajmg.b.32618. Epub 2018 Feb 20.

PMID:
29460498
11.

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. doi: 10.1158/1078-0432.CCR-17-2810. Epub 2018 Jan 22.

PMID:
29358504
12.

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.

JCI Insight. 2017 Dec 7;2(23). pii: 95665. doi: 10.1172/jci.insight.95665. [Epub ahead of print]

13.

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, Krispin R, Papir G, Sahly Y, Hayden MR.

Ann N Y Acad Sci. 2017 Nov;1407(1):75-89. doi: 10.1111/nyas.13547.

PMID:
29168242
14.

HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, Waltl S, Anderson L, Fazeli A, Casal L, Felczak B, Tsang M, Hayden MR.

Hum Mol Genet. 2018 Jan 15;27(2):239-253. doi: 10.1093/hmg/ddx394.

PMID:
29121340
15.

Epidemiology of Huntington disease.

Kay C, Hayden MR, Leavitt BR.

Handb Clin Neurol. 2017;144:31-46. doi: 10.1016/B978-0-12-801893-4.00003-1. Review.

PMID:
28947124
16.

Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.

Silva AC, Ferreira IL, Hayden MR, Ferreiro E, Rego AC.

Biochim Biophys Acta. 2018 Jan;1864(1):34-44. doi: 10.1016/j.bbadis.2017.09.009. Epub 2017 Sep 20.

PMID:
28939435
17.

Honey bees possess a polarity-sensitive magnetoreceptor.

Lambinet V, Hayden ME, Reid C, Gries G.

J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2017 Dec;203(12):1029-1036. doi: 10.1007/s00359-017-1214-4. Epub 2017 Sep 15.

PMID:
28916947
18.

ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels.

Trigueros-Motos L, van Capelleveen JC, Torta F, Castaño D, Zhang LH, Chai EC, Kang M, Dimova LG, Schimmel AWM, Tietjen I, Radomski C, Tan LJ, Thiam CH, Narayanaswamy P, Wu DH, Dorninger F, Yakala GK, Barhdadi A, Angeli V, Dubé MP, Berger J, Dallinga-Thie GM, Tietge UJF, Wenk MR, Hayden MR, Hovingh GK, Singaraja RR.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2147-2155. doi: 10.1161/ATVBAHA.117.309574. Epub 2017 Sep 7.

PMID:
28882873
19.

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M.

J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241.

PMID:
28826192
20.

Laquinimod treatment in the R6/2 mouse model.

Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R.

Sci Rep. 2017 Jul 10;7(1):4947. doi: 10.1038/s41598-017-04990-1.

Supplemental Content

Loading ...
Support Center